Immatics N.V.

What they do

Immatics discovers and develops T-cell receptor (TCR) based immunotherapies, including autologous and allogeneic approaches, for solid tumors. The company has multiple proprietary programs and collaborations with major pharmaceutical partners such as Bristol Myers Squibb, Moderna, and Genmab. Its pipeline includes TCR-T candidates targeting cancer-testis antigens and other targets.

Revenue drivers

• Collaboration agreements — Immatics generates revenue from research funding, license fees, and milestone payments under agreements with partners like Bristol Myers Squibb, Moderna, and Genmab. These collaborations provide upfront payments, reimbursement of research costs, and potential development and commercial milestones.
• Licensing and milestones — Revenue includes milestone payments upon achievement of preclinical, clinical, regulatory, and commercial events, as well as royalties on future product sales. For example, the Moderna collaboration included a $120 million upfront payment and up to $120 million in near-term milestones.
• Grant income — Immatics receives grants from government and non-profit organizations to support its research and development activities, though this is a smaller portion of total revenue.

Recent performance

In 2025, Immatics reported revenue from collaboration agreements, including amounts from Moderna and Genmab. The company continues to invest heavily in R&D, resulting in net losses. Cash and cash equivalents and other financial assets were €XXX million as of December 31, 2025, providing runway into 20XX. In 2024, the company completed public offerings raising gross proceeds of $XXX million.

Strategy

Immatics focuses on advancing its proprietary TCR-T pipeline, including lead candidate IMA203, and expanding its allogeneic platform. The company leverages partnerships to fund and accelerate development while retaining certain rights. It plans to initiate additional clinical trials and expand manufacturing capabilities. Strategic priorities include achieving clinical milestones and potentially securing additional collaborations.

Risks

• Clinical trial risks — Immatics' product candidates are in early stages, and there is no guarantee of successful clinical development or regulatory approval.
• Dependence on collaborations — A significant portion of revenue comes from a few partners; loss of or changes to these agreements could materially affect financial results.
• Financing needs — The company has incurred operating losses and may require additional capital to fund operations, which could be dilutive or unavailable on favorable terms.
• Competition — The immuno-oncology field is highly competitive, with many companies developing similar T-cell therapies.

Outlook

Management expects to continue advancing its clinical programs and may report additional data from ongoing trials. It anticipates receiving potential milestone payments from collaborations. The company's cash runway is expected to fund operations into 20XX, but future financing may be needed.